Table 2.

Clinical adverse experience summary for days 1–15 following each vaccination

	After dose 1				After dose 2				After dose 3
	qHPV		Placebo		qHPV		Placebo		qHPV		Placebo
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Subjects in analysis population	2020		2029		1931		1928		1855		1845
Subjects with follow-up	1945		1950		1860		1854		1806		1799
Number (%) of subjects:
With no adverse experiences	902	(46.4)	946	(48.5)	1071	(57.6)	1177	(63.5)	1097	(60.7)	1205	(67.0)
With one or more adverse experiences	1043	(53.6)	1004	(51.5)	789	(42.4)	677	(36.5)	709	(39.3)	594	(33.0)
Injection-site adverse experiences	863	(44.4)	813	(41.7)	698	(37.5)	558	(30.1)	628	(34.8)	500	(27.8)
Systemic adverse experiences	398	(20.5)	423	(21.7)	199	(10.7)	213	(11.5)	182	(10.1)	162	(9.0)
With vaccine-related† adverse experiences	924	(47.5)	877	(45.0)	738	(39.7)	611	(33.0)	653	(36.2)	538	(29.9)
Injection-site adverse experiences	862	(44.3)	812	(41.6)	698	(37.5)	558	(30.1)	628	(34.8)	500	(27.8)
Systemic adverse experiences	161	(8.3)	169	(8.7)	89	(4.8)	101	(5.4)	70	(3.9)	65	(3.6)
With serious adverse experiences	2	(0.1)	0	(0.0)	0	(0.0)	0	(0.0)	3	(0.2)	1	(0.1)
With serious vaccine-related adverse experiences	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Who died	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Discontinued‡ due to an adverse experience	2	(0.1)	1	(0.1)	0	(0.0)	3	(0.2)	0	(0.0)	0	(0.0)
Discontinued due to a vaccine-related adverse	2	(0.1)	1	(0.1)	0	(0.0)	2	(0.1)	0	(0.0)	0	(0.0)
experience
Discontinued due to a serious adverse	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
experience
Discontinued due to a serious vaccine-related	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
adverse experience

^†Determined by the investigator to be possibly, probably or definitely related to the vaccine.

^‡Discontinued = Subject discontinued from therapy. Percentages are calculated based on the number of subjects with follow-up.